First trials test targeting of α-synuclein for Parkinson disease

Lorraine V Kalia^{1

2

3}

Affiliations

¹ Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.
² Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.
³ Krembil Research Institute, University Health Network, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.

Comment

Lorraine V Kalia. Nat Rev Neurol. 2022 Dec.

. 2022 Dec;18(12):703-704.

doi: 10.1038/s41582-022-00726-6.

Lorraine V Kalia^{1

2

3}

¹ Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.
² Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.
³ Krembil Research Institute, University Health Network, Toronto, Ontario, Canada. lorraine.kalia@utoronto.ca.

No abstract available

Comment on

Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.

1. Devine, M. J. et al. Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun. 2, 440 (2011). - DOI - PubMed
1. Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839–840 (1997). - DOI - PubMed
1. Laperle, A. H. et al. iPSC modeling of young-onset Parkinson’s disease reveals a molecular signature of disease and novel therapeutic candidates. Nat. Med. 26, 289–299 (2020). - DOI - PubMed
1. Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson’s disease. N. Engl. J. Med. 387, 421–432 (2022). - DOI - PubMed
1. Lang, A. E. et al. Trial of cinpanemab in early Parkinson’s disease. N. Engl. J. Med. 387, 408–420 (2022). - DOI - PubMed